<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 2, Open-Label Study Evaluating the Efficacy and Safety of INCB054828 (FGFR Inhibitor)<br> in Subjects With Myeloid/Lymphoid Neoplasms With 8p11 Translocation Leading to FGFR1 Rearrangement
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-show2" href="images/study-rationale/Incyte ASCO 2017 TS mockup INC-1241 54828-203 (8p11) fight-203.jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav8">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav8">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav8">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top8" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content8">
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po8">
						<div class="absolute-cen">						
						<h3>Primary objective:</h3>
							<ul>
								<li>Evaluate the efficacy of INCB054828 (FGFR inhibitor)</li>
							</ul>
						<br>
						<h3>secondary objective:</h3>
							<ul>
								<li>Evaluate the safety of INCB054828</li>
							</ul>
						</div>
					</div>
					<!-- section 2 -->
					<div id="sd8">
						<div class="absolute-cen">						
						<h3>Study Design</h3>
						<img class="img-responsive" src="images/study-design/study-design8.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					
					<!-- section 3 -->
					<div id="kiec8">
						<div class="absolute-cen">
						<h3>Select inclusion criteria:</h3>
						<ul>
							<li>Age â‰¥18 years</li>
							<li>Documented myeloid/lymphoid neoplasms with 8p11 rearrangement known to lead to FGFR1 activation</li>
							<li>Subjects who are not candidates for stem cell transplant or have relapsed after transplant and delayed lymphocyte infusion, have progressed, and are not candidates for other disease-modifying therapies</li>
							<li>Eastern Cooperative Oncology Group performance status 0 to 2</li>
						</ul>
						<br>
						<h3>Select exclusion criteria:</h3>
						<ul>
							<li>Prior receipt of a selective FGFR inhibitor</li>
							<li>History and/or current evidence of ectopic mineralization/calcification</li>
							<li>Current evidence of corneal disorder/keratopathy confirmed by ophthalmologic examination</li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm8" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>CHR = complete hematologic response, CR = complete response, DOR = duration of response, FGFR = fibroblast growth factor receptor, FIGHT = Fibroblast Growth Factor Receptor Inhibitor in Oncology and Hematology Trials, OS = overall survival, PFS = progression-free survival, PR = partial response</p>
</div>